We are currently conducting numerous clinical trials in the areas described under Scope of Our Research Centers. Of the clinical trials we are conducting, below are the trials that are currently enrolling or seeking participants:
Migraines can contribute significantly to school absences, work loss, health care visits, and an overall impaired quality of life. Does your child suffer from migraines? Are they between 12 and 17 years old? If so, your child may qualify for a research study of an investigational medication.
Qualified participants will receive study medication and study-related visits at no cost, and may be compensated for time and travel. Health insurance is not needed to participate.
To see if your child may qualify call IMMUNOe International Research Centers at 303.773.9000. That's 303.773.9000.
A number of therapies currently available for Multiple Sclerosis are able to prevent damage from MS. However, none are able to repair damaged nerve tissue. This is a critical issue, especially for people with MS who already have some level of MS-related disability.
A new experimental drug is being tested that MAY address this critical gap in MS care. But before that can happen, this drug must be shown to be safe to administer to people with MS.
Dr. Ronald Murray and Dr. Isaac Melamed are seeking participants with MS who are willing to participate in a phase I trial to be among the first to receive this experimental drug.
Qualifications Include:
- Be between the age of 18-60
- Have a body mass index ≤ 30 (cannot be obese, okay if merely overweight)
- Have relapsing remitting OR secondary progressive MS (not primary progressive MS)
- Must be able to walk independently or with a cane for about 100 meters (may not participate if you depend on a walker)
Treatment with interferon beta (INF) or glatiramer acetate (GA) is allowed to continue during the study if therapy is stable for three months. Patients on Tysabri, Rituximab, Novantrone, or Fingolimod are not eligible to participate.
The study will last for 24 weeks. Compensation for time and travel will be provided.
If you believe you meet some of the criteria and are interested in participating in this important clinical trial, please call IMMUNOe International Research Centers at 303.773.9000 for more information.
Do you have a child under the age of four with asthma?
If so, IMMUNOe International Research Centers is currently seeking volunteers for an investigational asthma medication for children.
Qualifications:
- Between birth to 4 years of age
- Children between 2 and 4 must have been diagnosed with asthma
- Children between birth and 2 must have a history of asthma symptoms
This clinical research study will last a total of 35 days. All study related visits and medication is provided to you at no cost.
Participants may even be compensated for time and travel.
For more information, and to find out if your child qualifies, please contact IMMUNOe International Research Centers at 303.773.9000
Does your child suffer from gastroesophageal reflux disease or GERD?
Possible symptoms include poor weight gain, irritability, and refusal to eat even if your baby is hungry. If your child experiences these symptoms with little or no relief, he or she may qualify for an important research study.
IMMUNOe research centers are currently seeking participants for a pediatric GERD research study. We are currently enrolling infants from 1 to 11 months. All infants must have suspected, symptomatic or proven GERD. If qualified, all participants will receive study related medication and visits at no cost, and may even be compensated up to $280 for time and travel. Health insurance is not needed to participate.
If your child has suspected, symptomatic, or proven GERD diagnosis, he or she may qualify for this research study. Again, all study medication is provided at no cost to you, and health insurance is not needed.
Call 303.773.9000 to see if your infant qualifies. That's 303.773.9000, call now.
Have you been diagnosed with a primary immunodeficiency disease? Are you between the ages of 2 to 75 years of age, and currently receiving IVIG therapies?
If so, you may qualify for a research study that is being conducted in your area, for a new investigational IVIG therapy. If you have a confirmed diagnosis of CVID or XLA, you may be eligible to participate. Individuals who qualify and choose to participate will receive all study related medical visits, and study related medication at no cost. Participants may be compensated for time and travel. For more information about this new \ investigational IVIG therapy for those diagnosed with a primary immunodeficiency or PID, and to see if you qualify, please calls IMMUNOe International Research Centers at 303.773.9000. That's 303.773.9000
Have you had your shingles vaccine yet? Shingles is a painful rash that can develop from a dormant virus. Your risk for developing shingles progressively increases with age.
If you or a loved one is 70 years and older and have not had any previous vaccine against shingles or chicken pox, you may qualify for a research study of an investigational shingles vaccine, conducted by IMMUNOe International Research Centers.
Qualified participants will receive study vaccine and study-related visits at no cost, and may be compensated for time and travel. Health insurance is not needed to participate.
If you or a loved one is 70 years and older, you may qualify for this shingles vaccine research study.
To see if you may qualify, call IMMUNOe International Research Centers at 303.773.9000. That's 303.773.9000.
Study volunteers must meet the following criteria:
- Male or female between 6-11 years who is in general good health
- Must have demonstrated sensitivity to at least one seasonal allergen and have a history of seasonal allergic rhinitis/hay fever for at least 2 years
- Will refrain from using certain types of medications during an allotted time prior to the study and during the study
- Will avoid scheduling conflicts that could interfere with requires study visits
To see if you may qualify, call IMMUNOe International Research Centers at 303.773.9000. That's 303.773.9000.